Pharmacology of antithrombotic drugs: An assessment of oral antiplatelet and anticoagulant treatments

The Lancet

Volumn 386, Issue 9990, 2015, Pages 281-291

  Mega, Jessica L ^a   Simon, Tabassome ^b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ATOPAXAR; CLOPIDOGREL; DABIGATRAN; EDOXABAN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; TICAGRELOR; VORAPAXAR; WARFARIN; CYTOCHROME P450; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; THROMBOCYTE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84937630802     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60243-4     Document Type: Review

References (119)

1. B Furie, BC Furie Mechanisms of thrombus formation N Engl J Med 359 2008 938 949
2. F Franchi, DJ Angiolillo Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 2015 30 47
3. G Born, C Patrono Antiplatelet drugs Br J Pharmacol 147 suppl 1 2006 S241 S251
4. M Hamberg, J Svensson, B Samuelsson Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides Proc Natl Acad Sci USA 72 1975 2994 2998
5. PJ Loll, D Picot, RM Garavito The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase Nat Struct Biol 2 1995 637 643
6. C Patrono, LA García Rodríguez, R Landolfi, C Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
7. IH Benedek, AS Joshi, HJ Pieniaszek, SY King, DM Kornhauser Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers J Clin Pharmacol 35 1995 1181 1186
8. PG Steg, SK James, D Atar the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
9. PT O'Gara, FG Kushner, DD Ascheim the American College of Emergency Physicians the Society for Cardiovascular Angiography and Interventions 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 61 2013 485 510
10. SR Mehta, JP Bassand, S Chrolavicius the CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
11. EH Awtry, J Loscalzo Aspirin Circulation 101 2000 1206 1218
12. C Watala, J Golanski, J Pluta et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control Thromb Res 113 2004 101 113
13. C Patrono, B Rocca Drug insight: aspirin resistance - fact or fashion? Nat Clin Pract Cardiovasc Med 4 2007 42 50
14. B Rocca, F Santilli, D Pitocco et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes J Thromb Haemost 10 2012 1220 1230
15. D Capodanno, A Patel, K Dharmashankar et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease Circ Cardiovasc Interv 4 2011 180 187
16. P Barragan, J Sainsous, M Silvestri et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting Cathet Cardiovasc Diagn 32 1994 133 138
17. JM Lablanche, EP McFadden, JL Bonnet et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management Eur Heart J 17 1996 1373 1380
18. GJ Karrillon, MC Morice, E Benveniste et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry Circulation 94 1996 1519 1527
19. ME Bertrand, V Legrand, J Boland et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study Circulation 98 1998 1597 1603
20. P Barragan, P Pietri, P Villain, M Silvestri, PO Roquebert [Antiplatelet therapy during coronary endoprosthesis placement] Arch Mal Coeur Vaiss 89 suppl 1996 1515 1520 (in French).
21. ME Bertrand, HJ Rupprecht, P Urban, AH Gershlick the CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
22. S Yusuf, F Zhao, SR Mehta, S Chrolavicius, G Tognoni, KK Fox the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
23. JP Maffrand The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today? C R Chim 15 2012 737 743
24. SD Wiviott, E Braunwald, CH McCabe the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
25. L Wallentin, RC Becker, A Budaj the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
26. G Montalescot, L Bolognese, D Dudek the ACCOAST Investigators Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
27. G Montalescot, AW van't Hof Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 2337 2339
28. DL Bhatt, KA Fox, W Hacke the CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
29. L Mauri, DJ Kereiakes, RW Yeh the DAPT Study Investigators Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
30. MP Bonaca, DL Bhatt, E Braunwald et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial Am Heart J 167 2014 437 444 e5.
31. P Savi, JM Pereillo, MF Uzabiaga et al. Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
32. JL Rehmel, JA Eckstein, NA Farid et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 Drug Metab Dispos 34 2006 600 607
33. M Kazui, Y Nishiya, T Ishizuka et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
34. JT Brandt, CD Payne, SD Wiviott et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66 e9-16.
35. L Wallentin, C Varenhorst, S James et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
36. MT Roe, PW Armstrong, KA Fox the TRILOGY ACS Investigators Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
37. KN Garratt, WD Weaver, RG Jenkins et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after taxus liberté paclitaxel-eluting coronary stent placement Circulation 131 2015 62 73
38. JS Hulot, A Bura, E Villard et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
39. T Simon, C Verstuyft, M Mary-Krause the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
40. J-P Collet, J-S Hulot, A Pena et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
41. JL Mega, T Simon, JP Collet et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
42. T Simon, DL Bhatt, L Bergougnan et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects Clin Pharmacol Ther 90 2011 287 295
43. D Sibbing, W Koch, D Gebhard et al. Cytochrome 2C19∗17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
44. JD Roberts, GA Wells, MR Le May et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial Lancet 379 2012 1705 1711
45. TO Bergmeijer, PW Janssen, JC Schipper et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study Am Heart J 168 2014 16 22
46. Clinical Trials.gov. Tailored antiplatelet therapy following PCI (TAILOR-PCI). https://clinicaltrials.gov/ct2/show/NCT01742117?term=TAILOR-PCI&rank=1 (accessed March 2, 2015).
47. N von Beckerath, D Taubert, G Pogatsa-Murray, E Schömig, A Kastrati, A Schömig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial Circulation 112 2005 2946 2950
48. G Patti, G Colonna, V Pasceri, LL Pepe, A Montinaro, G Di Sciascio Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study Circulation 111 2005 2099 2106
49. G Montalescot, G Sideris, C Meuleman the ALBION Trial Investigators A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial J Am Coll Cardiol 48 2006 931 938
50. JP Collet, JS Hulot, G Anzaha the CLOVIS-2 Investigators High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2) JACC Cardiovasc Interv 4 2011 392 402
51. DJ Angiolillo, CM Gibson, S Cheng et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2011 65 74
52. GV Moukarbel, DL Bhatt Antiplatelet therapy and proton pump inhibition: clinician update Circulation 125 2012 375 380
53. ML O'Donoghue, E Braunwald, EM Antman et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
54. DL Bhatt, BL Cryer, CF Contant the COGENT Investigators Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
55. SG Goodman, R Clare, KS Pieper the Platelet Inhibition and Patient Outcomes Trial Investigators Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial Circulation 125 2012 978 986
56. T Simon, PG Steg, M Gilard et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry Circulation 123 2011 474 482
57. KJ Swiger, O Yousuf, KP Bliden, US Tantry, PA Gurbel Cigarette smoking and clopidogrel interaction Curr Cardiol Rep 15 2013 361
58. PA Gurbel, KP Bliden, DK Logan et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study J Am Coll Cardiol 62 2013 505 512
59. JH Cornel, EM Ohman, B Neely et al. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial Am Heart J 168 2014 76 87
60. MT Holmberg, A Tornio, M Neuvonen, PJ Neuvonen, JT Backman, M Niemi Grapefruit juice inhibits the metabolic activation of clopidogrel Clin Pharmacol Ther 95 2014 307 313
61. DJ Angiolillo, A Fernandez-Ortiz, E Bernardo et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
62. GW Stone, B Witzenbichler, G Weisz the ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
63. G Parodi, R Marcucci, R Valenti et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
64. L Bonello, J Mancini, M Pansieri et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel J Thromb Haemost 10 2012 1999 2005
65. D Erlinge, J Ten Berg, D Foley et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial J Am Coll Cardiol 60 2012 2032 2040
66. D Erlinge, PA Gurbel, S James et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 62 2013 577 583
67. MJ Price, PB Berger, PS Teirstein the GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
68. JP Collet, T Cuisset, G Rangé the ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
69. D Trenk, GW Stone, M Gawaz et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
70. F Mangiacapra, G Patti, E Barbato et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study JACC Cardiovasc Interv 5 2012 281 289
71. US Tantry, L Bonello, D Aradi the Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
72. D Aradi, JP Collet, J Mair the Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology and the Working Group on Thrombosis of the European Society of Cardiology Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost 113 2015 221 230
73. Clinical Trials.gov. Tailored antiplatelet therapy versus recommended dose of prasugrel (ANTARCTIC). https://clinicaltrials.gov/ct2/show/NCT01538446?term=antarctic&rank=1 (accessed March 2, 2015).
74. Clinical Trials.gov. Testing responsiveness to platelet inhibition on chronic antiplatelet treatment for acute coronary syndromes trial (TROPICAL-ACS). https://clinicaltrials.gov/ct2/show/NCT01959451?term=tropical+acs&rank=1 (accessed March 2, 2015).
75. S Husted, JJ van Giezen Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist Cardiovasc Ther 27 2009 259 274
76. PA Gurbel, KP Bliden, K Butler et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
77. G Parodi, R Valenti, B Bellandi et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
78. G Vilahur, BG Choi, MU Zafar et al. Normalization of platelet reactivity in clopidogrel-treated subjects J Thromb Haemost 5 2007 82 90
79. A Sugidachi, K Ohno, T Ogawa, J Jakubowski, M Hashimoto, A Tomizawa A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats Br J Pharmacol 169 2013 82 89
80. A Godier, G Taylor, P Gaussem Inefficacy of platelet transfusion to reverse ticagrelor N Engl J Med 372 2015 196 197
81. MT Holmberg, A Tornio, L Joutsi-Korhonen et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects Br J Clin Pharmacol 75 2013 1488 1496
82. M Cattaneo, R Schulz, S Nylander Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance J Am Coll Cardiol 63 2014 2503 2509
83. DJ Angiolillo, D Capodanno, S Goto Platelet thrombin receptor antagonism and atherothrombosis Eur Heart J 31 2010 17 28
84. DA Morrow, E Braunwald, MP Bonaca the TRA 2P-TIMI 50 Steering Committee and Investigators Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
85. V Capra, M Bäck, DJ Angiolillo, M Cattaneo, KS Sakariassen Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation J Thromb Haemost 12 2014 126 137
86. EW Davie, OD Ratnoff Waterfall Sequence for Intrinsic Blood Clotting Science 145 1964 1310 1312
87. JI Weitz Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease D Mann DP Zipes P Libby RO Bonow E Braunwald Braunwald's Heart Disease 10th edn. 2014 Elsevier Saunders Philadelphia, PA 1809 1833
88. KP Link The discovery of dicumarol and its sequels Circulation 19 1959 97 107
89. JY Chyou, JL Mega, MS Sabatine Pharmacogenetics EM Antman MS Sabatine Cardiovascular therapeutics 2013 Elsevier Saunders Philadelphia, PA 53 66
90. MA Crowther, J Julian, D McCarty et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial Lancet 356 2000 1551 1553
91. DS Budnitz, DA Pollock, KN Weidenbach, AB Mendelsohn, TJ Schroeder, JL Annest National surveillance of emergency department visits for outpatient adverse drug events JAMA 296 2006 1858 1866
92. DK Wysowski, P Nourjah, L Swartz Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch Intern Med 167 2007 1414 1419
93. LD Heimark, L Wienkers, K Kunze et al. The mechanism of the interaction between amiodarone and warfarin in humans Clin Pharmacol Ther 51 1992 398 407
94. JA Johnson, L Gong, M Whirl-Carrillo the Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing Clin Pharmacol Ther 90 2011 625 629
95. JL Anderson, BD Horne, SM Stevens et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation 125 2012 1997 2005
96. M Pirmohamed, G Burnside, N Eriksson the EU-PACT Group A randomized trial of genotype-guided dosing of warfarin N Engl J Med 369 2013 2294 2303
97. TI Verhoef, G Ragia, A de Boer the EU-PACT Group A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon N Engl J Med 369 2013 2304 2312
98. SE Kimmel, B French, SE Kasner the COAG Investigators A pharmacogenetic versus a clinical algorithm for warfarin dosing N Engl J Med 369 2013 2283 2293
99. I Zineh, M Pacanowski, J Woodcock Pharmacogenetics and coumarin dosing - recalibrating expectations N Engl J Med 369 2013 2273 2275
100. H Heidbuchel, P Verhamme, M Alings on behalf of European Heart Rhythm Association European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
101. LT Grip, RP Giugliano, CT Ruff New oral antithrombotic strategies: 2013 update on atrial fibrillation Hot Topics Cardiol 31 2013 7 18
102. S Blech, T Ebner, E Ludwig-Schwellinger, J Stangier, W Roth The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos 36 2008 386 399
103. CT Ruff, RP Giugliano, E Braunwald et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
104. SJ Connolly, MD Ezekowitz, S Yusuf the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
105. MR Patel, KW Mahaffey, J Garg the ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
106. CB Granger, JH Alexander, JJ McMurray the ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
107. RP Giugliano, CT Ruff, E Braunwald the ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
108. J Desai, JM Kolb, JI Weitz, J Aisenberg Gastrointestinal bleeding with the new oral anticoagulants - defining the issues and the management strategies Thromb Haemost 110 2013 205 212
109. JL Mega, E Braunwald, S Mohanavelu the ATLAS ACS-TIMI 46 study group Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
110. JH Alexander, RC Becker, DL Bhatt the APPRAISE Steering Committee and Investigators Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
111. J Oldgren, A Budaj, CB Granger the RE-DEEM Investigators Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
112. JL Mega, E Braunwald, SD Wiviott et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51) Am J Cardiol 112 2013 472 478
113. JH Alexander, RD Lopes, S James the APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
114. A Cuker, DM Siegal, MA Crowther, DA Garcia Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants J Am Coll Cardiol 64 2014 1128 1139
115. ClinicalTrials.gov. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). https://clinicaltrials.gov/ct2/show/NCT01830543?term=pioneer+af&rank=1 (accessed March 12, 2015).
116. ClinicalTrials.gov. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI). https://clinicaltrials.gov/ct2/show/NCT02164864?term=redual+pci&rank=1 (accessed March 2, 2015).
117. AR Harrington, EP Armstrong, PE Nolan Jr, DC Malone Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
118. JH You Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation - a cost-effectiveness analysis J Gen Intern Med 29 2014 438 446
119. JB Smith, AL Willis Aspirin selectively inhibits prostaglandin production in human platelets Nat New Biol 231 1971 235 237